<DOC>
	<DOC>NCT00622349</DOC>
	<brief_summary>The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC</brief_summary>
	<brief_title>Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histological or cytological diagnosis of nonsmall cell lung cancer Advanced (unresectable or functionally inoperable) stage III or stage IV disease Availability for participating in the detailed followup of the protocol Presence of an evaluable or measurable lesion Informed consent Prior treatment with chemotherapy Operable patient with resectable tumour Performance status &lt; 60 on the Karnofsky scale A history of prior malignant tumour, except nonmelanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5year disease free interval) Polynuclear cells &lt; 2,000/mm³ Platelet cells &lt; 100,000/mm³ Serum bilirubin &gt;1.5 mg/100 ml Serum creatinine &gt; 1.5 mg/100 ml and/or creatinine clearance &lt; 60 ml/min Perception hypoacousia Peripheral neuropathy Recent myocardial infarction (less than 3 months prior to date of diagnosis) Congestive cardiac failure requiring medical therapy or uncontrolled cardiac arrhythmia Uncontrolled infectious disease Serious medical or psychological factors which may prevent adherence to the treatment schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Randomised phase III</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Advanced non-small cell lung carcinoma</keyword>
</DOC>